Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2).
Denys P, Castaño Botero JC, Vita Nunes RL, Wachs B, Mendes Gomes C, Krivoborodov G, Tu LM, Del-Popolo G, Thompson C, Vilain C, Volteau M, Kennelly M; Dysport CONTENT program group. Denys P, et al. Among authors: kennelly m. Neurourol Urodyn. 2023 Jan;42(1):153-167. doi: 10.1002/nau.25062. Epub 2022 Nov 2. Neurourol Urodyn. 2023. PMID: 36321799 Free PMC article. Clinical Trial.
Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G, Moore C, Jenkins B, Guard S, Zheng Y, Karsenty G; 191622-094 Investigators. Kennelly M, et al. Neurourol Urodyn. 2017 Feb;36(2):368-375. doi: 10.1002/nau.22934. Epub 2015 Nov 24. Neurourol Urodyn. 2017. PMID: 26607743 Clinical Trial.
One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
Benson K, McCrery R, Taylor C, Padron O, Blok B, de Wachter S, Pezzella A, Gruenenfelder J, Pakzad M, Perrouin-Verbe MA, Van Kerrebroeck P, Mangel J, Peters K, Kennelly M, Shapiro A, Lee U, Comiter C, Mueller M, Goldman H, Lane F. Benson K, et al. Among authors: kennelly m. Neurourol Urodyn. 2020 Jun;39(5):1482-1488. doi: 10.1002/nau.24376. Epub 2020 Apr 27. Neurourol Urodyn. 2020. PMID: 32339339 Free PMC article.
Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system.
Pezzella A, McCrery R, Lane F, Benson K, Taylor C, Padron O, Blok B, de Wachter S, Gruenenfelder J, Pakzad M, Perrouin-Verbe MA, van Kerrebroeck P, Mangel J, Peters K, Kennelly M, Shapiro A, Lee U, Comiter C, Mueller M, Goldman HB. Pezzella A, et al. Among authors: kennelly m. Neurourol Urodyn. 2021 Feb;40(2):714-721. doi: 10.1002/nau.24615. Epub 2021 Jan 28. Neurourol Urodyn. 2021. PMID: 33508155 Free PMC article.
230 results